EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Puma Biotechnology's enterprise value is $265.3 Mil.
Puma Biotechnology's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $47.5 Mil. Therefore, Puma Biotechnology's EV-to-EBITDA for today is 5.58.
The historical rank and industry rank for Puma Biotechnology's EV-to-EBITDA or its related term are showing as below:
PBYI'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -600.56 Med: -8.2 Max: 11.72
Current: 5.58
During the past 13 years, the highest EV-to-EBITDA of Puma Biotechnology was 11.72. The lowest was -600.56. And the median was -8.20.
PBYI's EV-to-EBITDA is ranked better than 55.93% of 472
companies
in the Biotechnology industry
Industry Median: 9.005
vs PBYI: 5.58
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-24), Puma Biotechnology's stock price is $5.12.
Puma Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.450. Therefore, Puma Biotechnology's PE Ratio for today is 11.38.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Puma Biotechnology EV-to-EBITDA Historical Data
The historical data trend for Puma Biotechnology's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Puma Biotechnology's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Puma Biotechnology EV-to-EBITDA Distribution
For the Biotechnology industry and Healthcare sector, Puma Biotechnology's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Puma Biotechnology's EV-to-EBITDA falls into.
Puma Biotechnology EV-to-EBITDA Calculation
Puma Biotechnology's EV-to-EBITDA for today is calculated as:
Puma Biotechnology's current Enterprise Value is $265.3 Mil.
Puma Biotechnology's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $47.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Puma Biotechnology's PE Ratio for today is calculated as:
Puma Biotechnology's share price for today is $5.12.
Puma Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.450.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Puma Biotechnology's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Puma Biotechnology (Puma Biotechnology) Business Description
Puma Biotechnology Inc is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The company in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. FDA in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the US as NERLYNX.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PBYI has been successfully added to your 